MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.
Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.
The poster entitled “Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer” details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.
Enquiries
About Cytopia
Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.
The company’s lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009.
Website: www.cytopia.com.au
CONTACT: Dr. Gregg Smith, Director, Drug Development and Operations,
+61-3-9208-4234, gregg.smith@cytopia.com.au; or Mr. Andrew Macdonald, Chief
Executive Officer, +61-3-9208-4232, andrew.macdonald@cytopia.com.au
Web site: http://www.cytopia.com.au/
